2023
Pathological response in mucinous carcinoma of breast after neoadjuvant therapy - a multi-institutional study
Zhan H, Fineberg S, Podany P, Zeng J, Wang Y, Harigopal M, Singh K. Pathological response in mucinous carcinoma of breast after neoadjuvant therapy - a multi-institutional study. Human Pathology 2023, 142: 15-19. PMID: 37972873, DOI: 10.1016/j.humpath.2023.10.002.Peer-Reviewed Original ResearchConceptsNeoadjuvant endocrine therapyResidual tumour cellularityNeoadjuvant chemotherapyNeoadjuvant therapyMucinous carcinomaPathologic responseEndocrine therapyPathological responseMucin poolsBreast cancerEstrogen receptorTumor cellularityAcellular mucin poolsFavorable histologic subtypePreoperative adjuvant therapyRetrospective cohort studyComplete pathologic responseInvasive breast cancerNET groupMulti-institutional studyNeoadjuvant HER2Adjuvant therapyMC patientsCohort studyPathologic review
2020
HER2 immunohistochemistry staining positivity is strongly predictive of tumor response to neoadjuvant chemotherapy in HER2 positive breast cancer
Zhao J, Krishnamurti U, Zhang C, Meisel J, Wei Z, Suo A, Aneja R, Li Z, Li X. HER2 immunohistochemistry staining positivity is strongly predictive of tumor response to neoadjuvant chemotherapy in HER2 positive breast cancer. Pathology - Research And Practice 2020, 216: 153155. PMID: 32871536, DOI: 10.1016/j.prp.2020.153155.Peer-Reviewed Original ResearchConceptsHigh HER2/CEP17 ratioHER2/CEP17 ratioTumor responseBreast cancer casesNeoadjuvant HER2CEP17 ratioNeoadjuvant chemotherapyIHC 3Breast cancerCancer casesRCB II/IIIHER2-positive breast cancerHER2 IHC 3Complete pathologic responseResidual cancer burdenSmaller tumor sizePositive breast cancerLow nuclear gradeHER2 copy numberHigh Ki67Pathologic responseCancer burdenExcisional specimensPositive cancersTumor size
2014
Long-Term Follow-Up After Preoperative Trastuzumab and Chemotherapy for HER2-Overexpressing Breast Cancer
Mayer EL, Gropper AB, Harris L, Gold JM, Parker L, Kuter I, Come S, Najita JS, Guo H, Winer EP, Burstein HJ. Long-Term Follow-Up After Preoperative Trastuzumab and Chemotherapy for HER2-Overexpressing Breast Cancer. Clinical Breast Cancer 2014, 15: 24-30. PMID: 25205424, DOI: 10.1016/j.clbc.2014.07.010.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsChemotherapy, AdjuvantDisease-Free SurvivalFemaleFollow-Up StudiesHumansMastectomyMiddle AgedNeoadjuvant TherapyPreoperative PeriodReceptor, ErbB-2TrastuzumabTreatment OutcomeUp-RegulationConceptsHER2-positive breast cancerLong-term outcomesBreast cancerSymptomatic cardiotoxicityNeoadjuvant chemotherapyCardiotoxic agentsAdvanced HER2-positive breast cancerAnthracycline-based adjuvant chemotherapyFavorable long-term survivalPhase II neoadjuvant trialBreast cancer-related deathsHER2-positive diseaseMinimal late toxicityPaclitaxel/trastuzumabTreatment-related toxicityLong-term efficacyCancer-related deathLong-term survivalLong-term RFSAdjuvant chemotherapyEligible patientsLate cardiotoxicityNeoadjuvant HER2Neoadjuvant trastuzumabNeoadjuvant trials
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply